Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:815079.
doi: 10.1155/2012/815079. Epub 2012 Feb 12.

Proteomic profiling of thyroid papillary carcinoma

Yoshiyuki Ban  1 , Gou Yamamoto, Michiya Takada, Shigeo Hayashi, Yoshio Ban, Kazuo Shimizu, Haruki Akasu, Takehito Igarashi, Yasuhiko Bando, Tetsuhiko Tachikawa, Tsutomu Hirano
Affiliations

Proteomic profiling of thyroid papillary carcinoma

Yoshiyuki Ban et al. J Thyroid Res. 2012.

Abstract

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. We performed shotgun liquid chromatography (LC)/tandem mass spectrometry (MS/MS) analysis on pooled protein extracts from patients with PTC and compared the results with those from normal thyroid tissue validated by real-time (RT) PCR and immunohistochemistry (IHC). We detected 524 types of protein in PTC and 432 in normal thyroid gland. Among these proteins, 145 were specific to PTC and 53 were specific to normal thyroid gland. We have also identified two important new markers, nephronectin (NPNT) and malectin (MLEC). Reproducibility was confirmed with several known markers, but the one of two new candidate markers such as MLEC did not show large variations in expression levels. Furthermore, IHC confirmed the overexpression of both those markers in PTCs compared with normal surrounding tissues. Our protein data suggest that NPNT and MLEC could be a characteristic marker for PTC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Venn diagram of identified proteins. In PTC, 562 proteins were identified, and 498 were identified in normal thyroid tissue, with 462 proteins being common to both PTC and normal thyroid tissue. The total number of identified proteins was 598 (Normal; normal thyroid tissue; PTC; Papillary thyroid carcinoma).
Figure 2
Figure 2
Comparison of NSAF in the identified proteins in PTC tissues (n = 3) with NSAF in normal thyroid tissues (n = 3). Similar to previous reports, Keratin 19 (K1C19) and Dipeptidyl peptidase 4 (DPP4) were strongly expressed in PTC, and Fatty acid-binding protein 4 (FABP4) was strongly expressed in normal thyroid tissues. NPNT and MLEC were discovered as strongly expressed candidate markers in PTC (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma, ND: not detectable).
Figure 3
Figure 3
Gene expression of previously known markers (K1C19, DPP4, and FABP4) in normal thyroid tissue and PTC. Gene expression levels of K1C19 and DPP4 were significantly higher in PTC when compared with normal thyroid tissue. In contrast, FABP4 expression was lower (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma, *P < 0.05, Bar: 1 SD).
Figure 4
Figure 4
Gene expression of new candidate markers (NPNT and MLEC) in normal thyroid tissue and PTC. Gene expression of NPNT was significantly higher in PTC when compared with normal thyroid tissue. However, expression of MLEC showed no significant differences (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma, *P < 0.05, NS: not significant, Bar: 1 SD).
Figure 5
Figure 5
Immunohistochemical localization of NPNT and MLEC in normal thyroid tissue and PTC. Only weak staining of NPNT and MLEC were observed in follicular epithelium of normal thyroid tissue (surrounding tumor). In PTC, strong staining was seen with both antibodies (Normal: normal thyroid tissue, PTC: Papillary thyroid carcinoma).
See this image and copyright information in PMC

References

    1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83(12):2638–2648. - PubMed
    1. Gasent Blesa JM, Grande Pulido E, Provencio Pulla M, et al. Old and new insights in the treatment of thyroid carcinoma. Journal of Thyroid Research. 2010;2010:16 pages. Article ID 279468. - PMC - PubMed
    1. Fagin JA. Genetic basis of endocrine disease 3: molecular defects in thyroid gland neoplasia. Journal of Clinical Endocrinology and Metabolism. 1992;75(6):1398–1400. - PubMed
    1. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research. 2003;63(7):1454–1457. - PubMed
    1. Fagin JA. Challenging dogma in thyroid cancer molecular genetics—role of RET/PTC and BRAF in tumor initiation. Journal of Clinical Endocrinology and Metabolism. 2004;89(9):4264–4266. - PubMed

LinkOut - more resources